David Brindley, Managing Partner at IP Asset Ventures Ltd.
Dr David Brindley is an international research and industrial leader in healthcare translation. He holds academic appointments at the University of Oxford, Harvard, UCL, Stanford-UCSF-FDA Centre for Regulatory Sciences and CASMI, and is an enthusiastic and diligent advisor to a portfolio of healthcare sector companies, ranging from tools and technologies providers to life science focussed investors.
David is a Managing Partner at IP Asset Ventures Ltd. He is also Chief Scientific Officer of Aegate Ltd., who are world leaders in medicines authentication, ensuring compliance with the EU Falsified Medicines Directive (FMD) and US Drug Supply Chain Security Act (DSCSA).